Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박병배 | - |
dc.date.accessioned | 2017-06-12T01:33:39Z | - |
dc.date.available | 2017-06-12T01:33:39Z | - |
dc.date.issued | 2015-09 | - |
dc.identifier.citation | Blood Research, v. 50, NO 3, Page. 160-166 | en_US |
dc.identifier.issn | 2287-979X | - |
dc.identifier.issn | 2288-0011 | - |
dc.identifier.uri | http://www.bloodresearch.or.kr/journal/view.html?uid=1795&vmd=Full | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/27738 | - |
dc.description.abstract | Background Among the currently available prognostic models for diffuse large B-cell lymphoma (DLBCL), we investigated to determine which is most adoptable for DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) followed by upfront autologous stem cell transplantation (auto-SCT). Methods We retrospectively evaluated survival differences among risk groups based on the International Prognostic Index (IPI), the age-adjusted IPI (aaIPI), the revised IPI (R-IPI), and the National Comprehensive Cancer Network IPI (NCCN-IPI) at diagnosis in 63 CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT. Results At the time of auto-SCT, 74.6% and 25.4% of patients had achieved complete remission and partial remission after R-CHOP, respectively. As a whole, the 5-year overall (OS) and progression-free survival (PFS) rates were 78.8% and 74.2%, respectively. The 5-year OS and PFS rates according to the IPI, aaIPI, R-IPI, and NCCN-IPI did not significantly differ among the risk groups for each prognostic model (P-values for OS: 0.255, 0.337, 0.881, and 0.803, respectively; P-values for PFS: 0.177, 0.904, 0.295, and 0.609, respectively). Conclusion There was no ideal prognostic model among those currently available for CD20-positive DLBCL patients treated with R-CHOP followed by upfront auto-SCT. | en_US |
dc.language.iso | en | en_US |
dc.publisher | 대한혈액학회 | en_US |
dc.subject | Diffuse large B-cell lymphoma | en_US |
dc.subject | Hematopoietic stem cell transplantation | en_US |
dc.subject | Autologous transplantation | en_US |
dc.subject | Rituximab | en_US |
dc.subject | Prognostic groups | en_US |
dc.title | Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 50 | - |
dc.identifier.doi | 10.5045/br.2015.50.3.160 | - |
dc.relation.page | 160-166 | - |
dc.relation.journal | Blood Research | - |
dc.contributor.googleauthor | Lee, Hong Ghi | - |
dc.contributor.googleauthor | Kim, Sung-Yong | - |
dc.contributor.googleauthor | Kim, Inho | - |
dc.contributor.googleauthor | Kim, Yeo-Kyeoung | - |
dc.contributor.googleauthor | Kim, Jeong-A | - |
dc.contributor.googleauthor | Kim, Yang Soo | - |
dc.contributor.googleauthor | Lee, Ho Sup | - |
dc.contributor.googleauthor | Park, Jinny | - |
dc.contributor.googleauthor | Kim, Seok Jin | - |
dc.contributor.googleauthor | Park, Byeong-Bae | - |
dc.relation.code | 2015041102 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | bbpark | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.